You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDroperidol
Accession NumberDB00450  (APRD00939)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)

Structure
Thumb
Synonyms
1-(1-(3-(P-Fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-(1-(4-(P-Fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone
1-{1-[4-(4-fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[D]imidazol-2-one
Droperidol
Dropéridol
Droperidolo
Droperidolum
External Identifiers
  • McN-JR 4749
  • R 4749
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidol Injectionliquid2.5 mgintramuscular; intravenousNovopharm Limited1998-04-202002-03-14Canada
Droperidol Injection USP 2.5mg/mlsolution2.5 mgintramuscular; intravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Inapsineinjection2.5 mg/mLintramuscular; intravenousAkorn, Inc.1996-07-01Not applicableUs
Inapsineinjection2.5 mg/mLintramuscular; intravenousAkorn, Inc.1996-07-01Not applicableUs
Inapsine Inj 2.5mg/mlliquid2.5 mgintramuscular; intravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1982-12-311998-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousHospira, Inc.1988-02-29Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousCardinal Health1990-09-30Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-10-18Not applicableUs
Droperidolinjection, solution2.5 mg/mLintramuscular; intravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DehydrobenzperidolJanssen
DridolProstrakan
DroleptanDaiichi Sankyo
DropedolExcelsior
DropelSiu Guan
DroperdalCristália
DroperidolsGrindeks
XomolixArzneimittel ProStrakan
Brand mixtures
NameLabellerIngredients
Innovar InjJanssen Pharmaceutica, Division Of Janssen Ortho Inc.
SaltsNot Available
Categories
UNIIO9U0F09D5X
CAS number548-73-2
WeightAverage: 379.4274
Monoisotopic: 379.169605168
Chemical FormulaC22H22FN3O2
InChI KeyInChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
IUPAC Name
1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(=O)CCCN1CCC(=CC1)N1C(=O)NC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Butyrophenone
  • Benzimidazole
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Tetrahydropyridine
  • N-substituted imidazole
  • Hydropyridine
  • Gamma-aminoketone
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationDroperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
PharmacodynamicsDroperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias.
Mechanism of actionThe exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine(2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well.
Related Articles
AbsorptionCompletely absorbed following intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Extensively metabolized.

Route of eliminationNot Available
Half lifeBiphasic distribution. The rapid distribution phase is 1.4 ± 0.5 minutes and the slower distribution phase is 14.3 ± 6.5 minutes. Elimination half-life in adults is 134 ± 13 minutes and may be increased in geriatric patients. In children, it is 101.5 ± 26.4 minutes.
ClearanceNot Available
ToxicityThe intravenous LD50 of droperidol is 20-43 mg/kg in mice; 30 mg/kg in rats; 25 mg/kg in dogs and 11-13 mg/kg in rabbits. The intramuscular LD50 of droperidol is 195 mg/kg in mice, 104-110 mg/kg in rats; 97 mg/kg in rabbits and 200 mg/kg in guinea pigs. The manifestations of droperidol overdosage are an extension of its pharmacologic actions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9602
Caco-2 permeable-0.7521
P-glycoprotein substrateSubstrate0.7471
P-glycoprotein inhibitor IInhibitor0.9128
P-glycoprotein inhibitor IIInhibitor0.7451
Renal organic cation transporterInhibitor0.67
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8756
CYP450 3A4 substrateSubstrate0.6751
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.6353
CarcinogenicityNon-carcinogens0.9104
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5820 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8955
hERG inhibition (predictor II)Inhibitor0.835
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • Astrazeneca lp
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Solopak laboratories inc
  • Watson laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintramuscular; intravenous2.5 mg/mL
Solutionintramuscular; intravenous2.5 mg
Injectionintramuscular; intravenous2.5 mg/mL
Liquidintramuscular; intravenous2.5 mg
Liquidintramuscular; intravenous
Prices
Unit descriptionCostUnit
Inapsine 2.5 mg/ml ampul4.59USD ml
Droperidol 2.5 mg/ml vial2.04USD ml
Droperidol 2.5 mg/ml ampul0.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145-146.5Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium. Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
water solubility4.21 mg/LNot Available
logP3.50SANGSTER (1993)
pKa7.46SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0966 mg/mLALOGPS
logP3.93ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.72ChemAxon
pKa (Strongest Basic)6.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity109.52 m3·mol-1ChemAxon
Polarizability40.31 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Janssen, P.A.J. and Gardocki, J.F.; U.S. Patent 3,141,823; July 21, 1964; assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.
Januen, P.A.J.; U.S. Patent 3,161,645; December 15,1964: assigned to Research Laboratorium Dr. C. Janssen NV, Belgium.

US3161645
General ReferencesNot Available
External Links
ATC CodesN05AD08
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74 KB)
Interactions
Drug Interactions
Drug
AclidiniumAclidinium may increase the anticholinergic activities of Droperidol.
AlfentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Droperidol.
AlprazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.
AmisulprideThe risk or severity of adverse effects can be increased when Droperidol is combined with Amisulpride.
AmitriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
AmobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.
AmoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.
AmphetamineDroperidol may decrease the stimulatory activities of Amphetamine.
AripiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.
AzelastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Baclofen.
BenzphetamineDroperidol may decrease the stimulatory activities of Benzphetamine.
Botulinum Toxin Type ADroperidol may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BDroperidol may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.
BrimonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.
BromazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.
BromocriptineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.
BrompheniramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BuprenorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.
ButabarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
ButorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Droperidol.
CarbamazepineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbinoxamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.
CarisoprodolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.
CathinoneDroperidol may decrease the stimulatory activities of Cathinone.
CetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.
ChlordiazepoxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
ChlorphenamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.
ChlorpromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.
ChlorzoxazoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.
CimetropiumDroperidol may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Droperidol.
ClemastineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clemastine.
ClobazamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
ClomipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.
ClonazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.
ClonidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clonidine.
ClorazepateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.
ClozapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.
CyclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.
CyclobenzaprineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.
CyproheptadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DantroleneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DesfluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.
DesipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
DesloratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Droperidol.
Dexchlorpheniramine maleateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dexchlorpheniramine maleate.
DextroamphetamineDroperidol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Droperidol.
DiazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Droperidol.
DimenhydrinateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.
DiphenhydramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.
DofetilideDroperidol may increase the QTc-prolonging activities of Dofetilide.
DonepezilDonepezil may increase the central neurotoxic activities of Droperidol.
DoxepinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxylamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.
EfavirenzDroperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.
EluxadolineDroperidol may increase the activities of Eluxadoline.
EntacaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Droperidol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Droperidol.
EstazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Estazolam.
EszopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.
EthanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthosuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.
EthotoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.
EzogabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.
FelbamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.
FentanylDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.
FexofenadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.
FlibanserinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.
FlunarizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Droperidol.
FluphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
FlurazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Droperidol.
FosphenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Droperidol.
GabapentinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
gabapentin enacarbilDroperidol may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.
GalantamineGalantamine may increase the central neurotoxic activities of Droperidol.
Gamma Hydroxybutyric AcidDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Droperidol is combined with Glucagon recombinant.
GoserelinGoserelin may increase the QTc-prolonging activities of Droperidol.
GuanfacineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.
HaloperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HydrocodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.
HydroxyzineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.
ImipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Droperidol.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Droperidol.
IsofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Droperidol.
IvabradineIvabradine may increase the QTc-prolonging activities of Droperidol.
KetamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.
LamotrigineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Droperidol.
LevetiracetamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.
LevocetirizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Droperidol.
LevorphanolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Droperidol.
LisdexamfetamineDroperidol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Droperidol.
LoratadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loratadine.
LorazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Droperidol.
LoxapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
LurasidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
MaprotilineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
MeclizineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.
MeprobamateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.
MequitazineDroperidol may increase the arrhythmogenic activities of Mequitazine.
MetaxaloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MethadoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethamphetamineDroperidol may decrease the stimulatory activities of Methamphetamine.
MethocarbamolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.
MethohexitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MethotrimeprazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.
MidazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Droperidol.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Droperidol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
MirabegronThe risk or severity of adverse effects can be increased when Droperidol is combined with Mirabegron.
MirtazapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.
MorphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
NalbuphineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Droperidol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.
NitrazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.
Nitrous oxideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.
NortriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.
OctreotideOctreotide may increase the QTc-prolonging activities of Droperidol.
OlanzapineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
OlopatadineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
OrphenadrineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
OxycodoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.
OxymorphoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
ParaldehydeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Droperidol is combined with Paroxetine.
PentazocineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.
PentobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
PerphenazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
PethidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PhendimetrazineDroperidol may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Droperidol.
PhenobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.
PhentermineDroperidol may decrease the stimulatory activities of Phentermine.
PhenytoinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.
PipotiazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.
PizotifenDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.
PomalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Potassium ChlorideDroperidol may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Droperidol.
PregabalinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.
PrimidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Droperidol.
ProchlorperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Droperidol.
PromazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.
PromethazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
PropofolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Propofol.
ProtriptylineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
QuazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Droperidol.
RamelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.
RamosetronDroperidol may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.
RemifentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.
ReserpineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.
RisperidoneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
RivastigmineRivastigmine may increase the central neurotoxic activities of Droperidol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Droperidol.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Droperidol.
ScopolamineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.
Scopolamine butylbromideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine butylbromide.
SecobarbitalDroperidol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Droperidol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Droperidol.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Droperidol.
SevofluraneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
StiripentolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.
SufentanilDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Droperidol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Droperidol.
SuvorexantDroperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Droperidol can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.
TasimelteonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Droperidol.
TemazepamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Droperidol.
ThalidomideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiothixeneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.
TiagabineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.
TiotropiumDroperidol may increase the anticholinergic activities of Tiotropium.
TizanidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.
TolcaponeDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.
TopiramateDroperidol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.
TramadolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droperidol.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Droperidol.
TriazolamDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Droperidol.
TrifluoperazineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
TrimipramineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
TriprolidineDroperidol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Droperidol.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Droperidol.
VigabatrinDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Droperidol.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Droperidol.
ZaleplonDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.
ZiconotideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Droperidol.
ZolpidemDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.
ZopicloneDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Grip G, Svensson BA, Gordh T Jr, Post C, Hartvig P: Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat. Acta Anaesthesiol Scand. 1992 Feb;36(2):145-52. [PubMed:1549935 ]
  2. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092 ]
  3. Larson MD: The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia. Anesth Analg. 2003 Dec;97(6):1652-6. [PubMed:14633536 ]
  4. Gao HR, Shi TF, Yang CX, Zhang D, Zhang GW, Zhang Y, Jiao RS, Zhang H, Xu MY: The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats. J Neural Transm (Vienna). 2010 May;117(5):585-91. doi: 10.1007/s00702-010-0398-3. Epub 2010 Apr 1. [PubMed:20358234 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Zupko I, Janossy K, Maul K, Marki A, Falkay G: Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. [PubMed:12505540 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23